Biomedical subjects

Yukari Kondo

Publications and source records attributed to Yukari Kondo.

3 recordsLinked to original sources

PubMed2005

Crystallization and preliminary X-ray crystallographic studies of XynX, a family 10 xylanase from Aeromonas punctata ME-1.

Xylanases catalyze the hydrolysis of beta-1,4-glycosidic linkages within the xylan backbone. XynX is a xylanase from Aeromonas punctata ME-1 and belongs to glycoside hydrolase family 10. While most xylanases show endo-type catalytic activities, XynX shows exo-like catalytic activities, selectively producing xylobiose from birchwood xylan. In this study, XynX was crystallized by the hanging-drop vapour-diffusion method. The crystals belonged to the orthorhombic space group P2(1)2(1)2(1), with unit-cell parameters a = 79.0, b = 88.6, c = 93.2 A, and diffracted to beyond 1.8 A resolution.

Aeromonas↗

PubMed2005

[A patient care experience of the psychologically impaired cancer patient against chemotherapy--the successful outpatient case report using a sedative agent to reduce vomiting].

We would like to present a case report on how we managed to reduce an adverse effect of chemotherapy, specifically vomiting and nausea with a sedative agent diazepam, when a patient was intravenously injected with chemotherapeutic agents at the outpatient department. The patient was a 39-year-old female who experienced total hysterectomy and bilateral oophorectomy due to ovarian ca. (stage III) on May 29, 2002. She used to have complained of severe vomiting whenever undergoing 4-day inpatient chemotherapies every month from June 2002 to April 2003. In the last chemotherapy, she suffered vomiting prior to a day before the infusion and after 5 days of the infusion. Because of her experience, the patient refused to undergo the following chemotherapy. Based on discussions with her, use of sedatives was chosen to relieve vomiting. Due to relief of stress, the patient slept and relaxed by means of a sedative effect during and after administration of chemotherapy. Since the reduction of vomiting, she has been accepting further chemotherapies.

Adult↗

PubMed2003

Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2).

Osteoclast differentiation in the process of ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2) was examined to clarify the relationship between osteoclast development and rhBMP-2-induced bone formation. A combination of rhBMP-2 with a porous microsphere (PMS) and blood clot was implanted subcutaneously on the bilateral chest muscles of rats. Tartrate-resistant acid phosphatase (TRAPase) activity, cathepsin K (cath K), and calcitonin receptor (CTR), as markers of osteoclasts and their precursors, were examined using enzyme and immunohistochemical analysis up to 7 days after implantation. Mononuclear cells positive for TRAPase, cath K, and CTR first appeared on day 3 in connective tissue surrounding the PMS after implantation of rhBMP-2. Simultaneously, alkaline phosphatase activity became detectable in mesenchymal cells in the connective tissue. Electron microscopy demonstrated some mononuclear cells with abundant mitochondria and poorly developed rough endoplasmic reticulum in the proximity of mesenchymal cells. However, there was no evidence of cartilage or bone matrix formation on day 3. Osteoclasts in various stages of development, classified by the pattern of immunoreactivity for cath K, were observed by day 7. The polarized intracellular distribution of cath K was found only in osteoclasts attached to bone matrix. In conclusion, we have demonstrated for the first time the appearance of osteoclast precursors before bone matrix formation induced by rhBMP-2, suggesting that bone matrix is not a prerequisite for osteoclast precursor recruitment. Furthermore, we suggest that differentiation into polarized functional osteoclasts is accomplished when the osteoclasts attach to the bone matrix.

Animals↗